Skip to main content

Table 2 Comparison of anticancer therapies between groups

From: The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis

variable TB treatment
n (%)
Lung cancer
n (%)
P value
treatment line of anti-cancer chemotherapy
 Adjuvant treatment 3 (9.7) 9 (17.6) 0.056
 First line 25 (80.6) 42 (82.4)  
 Second line or later 3 (9.7) 0 (0)  
Chemotherapy regimen
 Single agent 5 (16.1) 10 (19.5) 0.308
 Gemcitabine 3 (9.7) 2 (3.9)  
 Pemetrexed 1 (3.2) 2 (3.9)  
 Etoposide 0 4 (7.8)  
 Paclitaxel 1 (3.2) 2 (3.9)  
 Two agents 26 (83.9) 41 (80.5) 0.879
 Gemcitabine plus platinum 12 (38.7) 15 (29.4)  
 Pemetrexed plus platinum 7 (22.6) 14 (27.5)  
 Etoposide plus platinum 6 (19.4) 10 (19.6)  
 Paclitaxel plus platinum 1 (3.2) 2 (3.9)  
Cycles of chemotherapy 4 (3–6) 5 (4–6) 0.923
Treatment completion rate
 Completion 27 (87.1) 47 (92.2) 0.454
 Active withdrawal 4 (12.9) 4 (7.8)  
Response    0.322
 Complete response 0 (0) 1 (2.0)  
 Partial response 2 (6.5) 4 (7.8)  
 Stable disease 22 (70.9) 40 (78.4)  
 Progressive disease 7 (22.6) 6 (11.8)  
Median survival (weeks) 52 (22–82) 57 (36–64) 0.505
 Non-small cell (stage III/IV) 52 (26–82)
(n = 22)
48 (32–64)
(n = 29)
0.331
 Small cell (stage III/IV) 22 (21–33)
(n = 6)
52 (40–57)
(n = 13)
0.323
KPS change    0.715
 Increase 2 (6.5) 10 (19.6)  
 Decrease 2 (6.5) 1 (2.0)  
 No change 27 (87.1) 40 (78.4)